AE Wealth Management LLC Acquires 6,647 Shares of Eli Lilly and Company (NYSE:LLY)

AE Wealth Management LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 11.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 63,613 shares of the company’s stock after buying an additional 6,647 shares during the period. AE Wealth Management LLC’s holdings in Eli Lilly and Company were worth $57,593,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. King Luther Capital Management Corp boosted its holdings in Eli Lilly and Company by 1.9% in the 2nd quarter. King Luther Capital Management Corp now owns 129,181 shares of the company’s stock worth $116,958,000 after buying an additional 2,397 shares during the period. Simplify Asset Management Inc. boosted its holdings in Eli Lilly and Company by 41.9% in the 2nd quarter. Simplify Asset Management Inc. now owns 11,412 shares of the company’s stock worth $10,332,000 after buying an additional 3,371 shares during the period. Bridges Investment Management Inc. boosted its holdings in Eli Lilly and Company by 14.5% in the 2nd quarter. Bridges Investment Management Inc. now owns 11,361 shares of the company’s stock worth $10,286,000 after buying an additional 1,436 shares during the period. Callan Capital LLC boosted its holdings in Eli Lilly and Company by 15.7% in the 2nd quarter. Callan Capital LLC now owns 3,943 shares of the company’s stock worth $3,570,000 after buying an additional 536 shares during the period. Finally, Canada Pension Plan Investment Board boosted its holdings in Eli Lilly and Company by 17.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 927,153 shares of the company’s stock worth $839,426,000 after buying an additional 137,418 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $915.04 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $972.53. The firm has a market capitalization of $869.66 billion, a P/E ratio of 134.76, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company’s 50-day moving average is $895.62 and its 200 day moving average is $836.99.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were paid a $1.30 dividend. The ex-dividend date was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 17,229 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $902.38, for a total value of $15,547,105.02. Following the transaction, the insider now directly owns 97,556,910 shares in the company, valued at approximately $88,033,404,445.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 442,229 shares of company stock worth $410,002,456 in the last three months. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on LLY shares. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price target for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Barclays boosted their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.